glp 1 agonists addiction Not just obesity: GLP-1 receptor advance on IUPHAR review – Glucagon-like peptide-1

New FDA regulations and legal actions are phasing out compounded GLP-1s, while companies introduce lower-priced, FDA-approved alternatives.

Currently, there are ten classes of orally available pharmacological agents to treat T2DM: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, 9) sodium-glucose transport protein 2 (SGLT2) inhibitors and 10) oral glucagon like peptide 1 (GLP-1) receptor agonists

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

Results The final report includes 50 studies

The weight loss medications can be part of a long-term treatment strategy for adults, according to new World Health Organization guidelines.